The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in Japan has terminated effective 30 November. SymBio is seeking damages of at least $82m (¥9bn) arising from MDCO’s repudiation of the licence agreement. The termination is in line with our expectations after MDCO voluntarily withdrew IONSYS from sale in the US market in June; any compensation payments received from MDCO would represent upside
15 Dec 2017
Licence agreement for IONSYS terminated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Licence agreement for IONSYS terminated
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
15 Dec 2017 -
Author:
Dr Dennis Hulme -
Pages:
3
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in Japan has terminated effective 30 November. SymBio is seeking damages of at least $82m (¥9bn) arising from MDCO’s repudiation of the licence agreement. The termination is in line with our expectations after MDCO voluntarily withdrew IONSYS from sale in the US market in June; any compensation payments received from MDCO would represent upside